Poster
CHOK1-ADCC+
CHOK1-ADCC+: High-Performance Host Cell System
for ADCC Biotherapeutics
Abstract
Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) is a key mechanism where
antibodies recruit immune cells (e.g. NK cells) to destroy target cells. This process is critical
for enhancing immunotherapies against cancer by allowing immune cells to recognize target
cells specifically, while minimizing the damage to other cells. The major challenge in
ADCC drug development is the non-specific binding of endogenous IgG to the FcγIIIa
on NK cells. Glycoengineering offers a strategy to overcome this challenge. Removing
fucose significantly enhances FcγRIIIa binding, boosting ADCC potency.
Here, we present a FUT-8 knockout CHO host cell platform, CHOK1-ADCC+, to produce
afucosylated antibodies. The engineered host cell shows high productivity, achieving titers
of up to 10g/L, excellent stability and scalability, while ensuring ADCC potency. By combining
enhanced ADCC efficacy with industrial-scale productivity, our CHOK1-ADCC+ host
cell system offers a complete and ready-to-implement solution for the development of
next-generation cancer immunotherapies.
CHOK1-ADCC+ Host Cell
CLD Services
ADCC Effect Evaluation
High productivity
ProGram Fast: Fast sample preparation
Glycan profiling:
mAb: 6-10 g/L
5 weeks from gene synthesis to
LC-MS & HPLC
Symmetric bsAb: 7-8 g/L
Asymmetric bsAb: 4.5-7 g/L
purified afucosylated antibody
ADCC potency evaluation:
Cell Line Development
Affinity to Fcγ receptor (CD16a)
Reporter gene assay
With IND clearance record
12 weeks from gene synthesis to
top 6 clones
Proprietary cell line with no IP issue
PBMC-based assay
16 weeks from gene synthesis to
top 1 clone
Case Study
Excellent Productivity and Stability
Enabling Process Scale-Up
~6g/L prior to process development
Stable PCB performance across 60 PDLs
Consistent growth performances and key quality
attributes in process scale-up from 3L to 150L
ProBioCDMO.com